Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

EDA2R gene linked to hair loss.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This study found that three genetic loci, including the newly identified JMJD1C, are associated with circulating testosterone and dihydrotestosterone levels, explaining a small portion of their variance in European men.

TGF-β1 from dermal papilla cells suppresses hair growth, and targeting it may help treat androgenetic alopecia.

This article reviews the potential impact of melatonin on hair growth, noting its benefits observed in animals, but reports no clinical results in humans to date.

This study reports that the same androgen receptor gene mutation within a family can lead to both complete and partial androgen insensitivity syndromes, suggesting that genetic defects alone may not predict clinical phenotype.

High-dose androgen therapy can help manage certain types of androgen resistance.

This article discusses treatment approaches for female pattern hair loss and concludes that available medical treatments are effective in reversing or stabilizing the condition in most cases of mild-to-moderate severity.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

This study found an association between abnormally high plasma testosterone concentrations and aggressive behaviors in certain autistic individuals.

This review highlights the efficacy of transdermal testosterone therapy in improving sexual function in women with hypoactive sexual desire disorder, though approved formulations and long-term safety data are limited.

This study found that platelet-rich plasma injections led to improvements in hair counts, thickness, and strength in patients with androgenic alopecia, showing promise as an effective treatment with no major adverse effects.

Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.

This study found that new curcumin analogues, such as ASC-J9, can inhibit prostate cancer cell growth by promoting androgen receptor degradation.

In this case series, researchers observed androgenetic alopecia in 20 prepubertal children with a strong genetic predisposition, despite the condition typically not occurring before puberty.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This research paper reviews the anti-androgenic properties of the drug flutamide and its metabolite Sch 16423 but presents no new experimental results.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

This study found that women with PCOS have elevated serum androgen levels throughout adulthood, with these levels decreasing and variations increasing as they approach menopause.

This study found a high prevalence of clinical signs and functional disorders of androgen excess in premenopausal women, with idiopathic hyperandrogenism and idiopathic hirsutism rates similar to PCOS.

This study explored the interaction between androgen and Wnt signaling in dermal papilla cells, targeting the effects of androgen on hair growth reduction.

Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.

This study found a significant association between androgenetic alopecia and metabolic syndrome, highlighting high-density lipoprotein cholesterol as a particularly important factor.

This study found that hair thickness and density increased after treatment with human follicle mesenchymal stem cells and platelet rich plasma, associated with enhanced Wnt signaling and platelet derived growth factors.

This case series found that adding microneedling to conventional finasteride and minoxidil therapy for androgenetic alopecia improved new hair growth and patient satisfaction in poor responders.

This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.